Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Receivables (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Receivables for 16 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 52.78% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$408000.0, a 87.88% increase, with the full-year FY2025 number at -$408000.0, up 87.88% from a year prior.
  • Change in Receivables was $1.5 million for Q4 2025 at Anika Therapeutics, up from -$1.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $6.2 million in Q2 2023 to a low of -$4.8 million in Q3 2024.
  • A 5-year average of $468850.0 and a median of $1.3 million in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: soared 285.53% in 2021, then tumbled 959.27% in 2023.
  • Anika Therapeutics' Change in Receivables stood at -$2.1 million in 2021, then soared by 130.74% to $647000.0 in 2022, then surged by 70.63% to $1.1 million in 2023, then soared by 196.38% to $3.3 million in 2024, then tumbled by 52.78% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Change in Receivables are $1.5 million (Q4 2025), -$1.3 million (Q3 2025), and $2.4 million (Q2 2025).